Therakos

What Therakos does

Therakos is a specialty healthcare company that develops, manufactures, and distributes the THERAKOS CELLEX Photopheresis System — the only fully integrated FDA-approved extracorporeal photopheresis (ECP) device — together with the UVADEX (methoxsalen) Sterile Solution. The ECP procedure collects a patient's white blood cells, treats them with methoxsalen and ultraviolet-A light inside a closed system, and returns the modulated cells to the patient to drive immunomodulation. Indicated uses include the palliative treatment of skin manifestations of Cutaneous T-Cell Lymphoma (CTCL), steroid-refractory chronic graft-versus-host disease (GvHD), and solid organ transplant rejection (heart and lung).

The business sells capital equipment (the CELLEX system) to treatment centers plus recurring consumables (single-use procedure kits and UVADEX drug) for every treatment performed, generating a razor-and-blade revenue model. Go-to-market is enterprise field sales through Therakos Business Managers targeting academic medical centers, university hospitals, and independent infusion centers in more than 30 countries, supported by the MyTherakos professional portal, Therakos Total Care patient support, and the Therakos Institute training platform. The installed base exceeds 300 treatment centers globally with over 1 million cumulative treatments delivered since 1987.

In November 2024, CVC Capital Partners acquired Therakos from Mallinckrodt Pharmaceuticals, with Mallinckrodt providing transition services under a TSA. Therakos operates as a privately held platform with regional entities in the US, Canada, UK, Ireland, Australia, and Japan, and continues to invest in indication expansion (GvHD, transplant rejection), geographic footprint, and the operator-education ecosystem that underwrites its regulatory and switching-cost advantages.

Name

Therakos

Legal name

Therakos LLC

Website

https://therakos.com

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Therakos manufactures the only FDA-approved integrated extracorporeal photopheresis system (THERAKOS CELLEX) and the UVADEX drug, selling capital equipment and recurring procedure consumables to 300+ treatment centers in 30+ countries for CTCL, GvHD, and transplant rejection.

Ownership category

akta.pro rank

Headquarters

HQ city

Raritan

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device and Drug Sales: Therakos generates revenue through the sale of the THERAKOS CELLEX Photopheresis System hardware, single-use procedure kits, and UVADEX (methoxsalen) sterile solution. Treatment centers purchase the system and consumables for performing extracorporeal photopheresis procedures on patients.
2. Procedure Kits and Consumables: Disposable procedure kits are used only once and discarded after each treatment, creating recurring revenue from consumables for each procedure performed.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Therakos develops, manufactures, and sells the THERAKOS CELLEX Photopheresis System, an FDA-approved extracorporeal photopheresis (ECP) medical device, together with the UVADEX (methoxsalen) Sterile Solution used as the photoactive drug during the procedure. The combined system is sold to hospitals, academic medical centers, and treatment centers for the palliative treatment of skin manifestations of Cutaneous T-Cell Lymphoma (CTCL) unresponsive to other therapies, with the procedure generating recurring demand for single-use procedure kits and UVADEX consumables.

Product overview

Therakos offers the THERAKOS CELLEX Photopheresis System as its core medical device product, used in conjunction with UVADEX (methoxsalen) Sterile Solution for extracorporeal photopheresis (ECP) treatment. The system performs a closed-loop procedure that collects white blood cells, treats them with the photoactive drug and UVA light, and returns them to the patient. Supporting offerings include the MyTherakos patient portal for healthcare professionals, Therakos Total Care patient support program, and the Therakos Institute professional education platform. The company has been acquired by CVC (November 2024) from Mallinckrodt Pharmaceuticals, with operations spanning over 30 countries and delivering over 1 million treatments globally.

Differentiator

Problem solved

Functional benefit

Brands

• THERAKOS CELLEX Photopheresis System: The world's only fully integrated and validated ECP (extracorporeal photopheresis) system used for immunomodulatory treatment of CTCL, GvHD, and solid organ transplant rejection.
• UVADEX (methoxsalen) Sterile Solution
• Therakos Total Care
• Therakos Institute
• MyTherakos

Products and services

• THERAKOS CELLEX Photopheresis System FDA-approved extracorporeal photopheresis (ECP) medical device that collects, separates, and treats white blood cells with UVADEX and UVA light inside a single closed system before returning them to the patient. Used by hospitals and academic medical centers for palliative treatment of CTCL skin manifestations unresponsive to other therapies.
• UVADEX (methoxsalen) Sterile Solution Photoactive 8-methoxypsoralen (8-MOP) sterile solution indicated for extracorporeal administration with the THERAKOS CELLEX Photopheresis System in the palliative treatment of skin manifestations of CTCL unresponsive to other forms of treatment. Sold to treatment centers as a single-use drug consumed during each ECP procedure.
• Therakos Total Care Customer support program offering assistance with treatment access, financial support, and reimbursement resources for patients undergoing Therakos photopheresis treatment and for the healthcare providers delivering it.
• Therakos Institute Professional education and training program that helps build a community of expert ECP operators through webinars, e-learning courses, expert consultation, and Centre of Excellence bookings for healthcare professionals using the CELLEX System.

Quantifiable outcome

• ORR at Months 3-4: 45.34% (95% CI: 26.64-65.45); ORR at Months 6-8: 58.23% (95% CI: 45.04-70.35)
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Mallinckrodt PharmaceuticalsminorOthers · 29 November 2024Following CVC's acquisition of Therakos, some systems and services continue to be operated by Mallinckrodt Pharmaceuticals under a Transition Services Agreement (TSA) during the transition period.
• South-Pest Central Hospital, National Institute of Hematology and InfectiologycoreStrategic or Co-development PartnerAward recipient Dr. Andrea Varkonyi and team conducting retrospective and prospective study comparing ruxolitinib alone to ruxolitinib combined with ECP therapy in treatment of acute and chronic GvHD, evaluating impact on TA-TMA development.
• European Bone Marrow Transplant (EBMT) MeetingminorStrategic or Co-development PartnerTherakos collaborated with EBMT to host symposia celebrating 30 years of ECP in GvHD at the 2024 EBMT Annual Meeting in Glasgow, including clinical and nurse-focused educational sessions.
• GvHD HubminorGTM or Marketing PartnerGvHD Hub partnered with Therakos to present a symposium on 30 years of ECP in GvHD: Recommendations for treatment of cGvHD during the 2024 EBMT Annual Meeting.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Incyte Corporation: Specialty biopharmaceutical company whose drug ruxolitinib (Jakafi) is a primary oral therapy for steroid-refractory GvHD and is being studied in combination with ECP. Comparable to Therakos because both compete for the same GvHD patient population, making Incyte a therapeutic alternative in the addressable patient pool.
• B. Braun: Diversified medical device and pharmaceutical company that produces apheresis and blood-treatment products alongside infusion therapy, surgical, and hospital care lines. Comparable to Therakos in the apheresis device and consumables category, though operating as a much broader portfolio incumbent.
• Bristol-Myers Squibb: Large oncology company with approved therapies for cutaneous T-cell lymphoma (e.g., mogamulizumab) and other hematology indications overlapping Therakos' CTCL franchise. Comparable as a therapeutic alternative for the same CTCL patient segment using different mechanisms.
• Astellas Pharma: Global pharmaceutical company with a leading transplant franchise (tacrolimus and other immunosuppressants) used to prevent and treat rejection after solid organ transplantation. Comparable to Therakos because its products serve the same transplant patient population in which ECP is also used to manage rejection.
• Sanofi (Kiadis): Through its acquisition of Kiadis, Sanofi is commercializing an off-the-shelf cell therapy for patients undergoing hematopoietic stem cell transplantation, addressing GvHD risk. Comparable to Therakos because both target immunomodulation in the post-transplant setting and compete for transplant-related patient treatment decisions.

Direct peers

• Haemonetics: Medical device company specializing in blood and apheresis component collection systems sold to hospitals and blood centers. Closely comparable to Therakos given its apheresis hardware plus single-use disposable consumables business model serving hospital-based treatment centers.
• Terumo BCT: Subsidiary of Terumo focused on blood component collection, therapeutic apheresis, and cell processing systems. Directly comparable to Therakos as a competing supplier of extracorporeal cell-therapy and apheresis instruments sold with proprietary disposable kits to hospitals and treatment centers worldwide.
• Fresenius Medical Care: Global leader in dialysis and apheresis therapies, offering blood-purification and extracorporeal treatment systems used in hospitals and treatment centers. Highly comparable to Therakos because both operate in extracorporeal blood-treatment devices for specialty therapies with consumable-driven recurring revenue.

Emerging players

• Mesoblast: Cell therapy developer with approved and late-stage allogeneic cell therapies for steroid-refractory GvHD and other inflammatory conditions. Comparable to Therakos as a competing modality for GvHD treatment that could displace or complement ECP in transplant-related indications.

Others

• Mallinckrodt Pharmaceuticals: Specialty pharmaceutical company that owned Therakos until divesting it to CVC in November 2024 and continues to provide transition services. Highly comparable context as the prior corporate parent in specialty drugs and rare diseases, governing how Therakos' standalone operations are being built out under TSA.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/c/therakos
• Facebookfacebook.com/TherakosPhotopheresis
• LinkedInlinkedin.com/company/therakos-inc

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Therakos